Nicotine exposure and the progression of chronic kidney disease: role of the α7-nicotinic acetylcholine receptor

Am J Physiol Renal Physiol. 2012 Jul 15;303(2):F304-12. doi: 10.1152/ajprenal.00661.2011. Epub 2012 May 2.

Abstract

Clinical studies have established the role of cigarette smoking as a risk factor in the progression of chronic kidney disease (CKD). We have shown that nicotine promotes mesangial cell proliferation and hypertrophy via nonneuronal nicotinic acetylcholine receptors (nAChRs). The α7-nAChR is one of the most important subunits of the nAChRs. These studies were designed to test the hypothesis that nicotine worsens renal injury in rats with 5/6 nephrectomy (5/6Nx) and that the α7-nAChR subunit is required for these effects. We studied five different groups: Sham, 5/6Nx, 5/6Nx + nicotine (Nic; 100 μg/ml dry wt), 5/6Nx + Nic + α7-nAChR blocker methyllicaconitine (MLA; 3 mg·kg(-1)·day(-1) sq), and Sham + Nic. Blood pressure was measured by the tail-cuff method, and urine was collected for proteinuria. After 12 wk, the rats were euthanized and kidneys were collected. We observed expression of the α7-nAChR in the proximal and distal tubules. The administration of nicotine induced a small increase in blood pressure and resulted in cotinine levels similar to those found in the plasma of smokers. In 5/6Nx rats, the administration of nicotine significantly increased urinary protein excretion (onefold), worsened the glomerular injury score and increased fibronectin (∼ 50%), NADPH oxidase 4 (NOX4; ∼100%), and transforming growth factor-β expression (∼200%). The administration of nicotine to sham rats increased total proteinuria but not albuminuria, suggesting direct effects on tubular protein reabsorption. These effects were prevented by MLA, demonstrating a critical role for the α7-nAChR as a mediator of the effects of nicotine in the progression of CKD.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aconitine / analogs & derivatives
  • Aconitine / pharmacology
  • Animals
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Chronic Disease
  • Disease Models, Animal
  • Disease Progression*
  • Kidney Diseases / etiology
  • Kidney Diseases / metabolism
  • Kidney Diseases / physiopathology*
  • Male
  • NADPH Oxidase 4
  • NADPH Oxidases / metabolism
  • Nephrectomy / adverse effects
  • Nicotine / adverse effects*
  • Nicotine / pharmacology
  • Nicotinic Antagonists / pharmacology
  • Oxidative Stress / drug effects
  • Oxidative Stress / physiology
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Nicotinic / drug effects
  • Receptors, Nicotinic / physiology*
  • Transforming Growth Factor beta / metabolism
  • alpha7 Nicotinic Acetylcholine Receptor

Substances

  • Chrna7 protein, rat
  • Nicotinic Antagonists
  • Receptors, Nicotinic
  • Transforming Growth Factor beta
  • alpha7 Nicotinic Acetylcholine Receptor
  • methyllycaconitine
  • Nicotine
  • NADPH Oxidase 4
  • NADPH Oxidases
  • Nox4 protein, rat
  • Aconitine